Navigation Links
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Date:7/14/2008

in MAP0004 is dihydroergotamine (DHE), which has a long history of use as a safe and effective migraine treatment. Many headache specialists consider DHE administered by injection to be the standard of care in treating chronic migraine and debilitating migraines that last more than 72 hours. MAP Pharmaceuticals is seeking to expand the use of this compound to treat migraines early, non-invasively and with a fast onset of action.

MAP Pharmaceuticals is initiating the first Phase 3 trial of its MAP0004 product candidate pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration. The SPA is intended to provide assurance that if pre-specified trial results are achieved, they may serve as the primary basis for an efficacy claim in support of a new drug application. In general, these assessments are considered binding on the FDA as well as the sponsor unless public health concerns unrecognized at the time the SPA is entered into become evident or other new scientific concerns regarding product safety or efficacy arise.

About Migraine

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States. It presents with recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. Most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly.

In published studies, migraine sufferers often cite faster onset of pain relief and lower incidence of migraine recurrence as two key therapeutic attributes they would like from their medication. Currently approved drugs for the treatment of an acute migraine attack do not fully meet the needs of all patients due to the slow onset of action, short duration of effect, inconsistent response, unacceptable side effect profiles, or propensity to increa
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 /CNW/ - Today, the Honourable Rona Ambrose, ... animal health organizations to discuss the Government of ... (AMR). The roundtable provided an important ... share their priorities and discuss roles and responsibilities in ... their optimal use (also known as antimicrobial stewardship) was ...
(Date:3/31/2015)... 2015 Point-of-Care Partners, a leading health ... has launched the ePA State Navigator -- a ... payers and pharmacies to quickly assess the evolving ... of prescription medications. Today, the majority ... through time-consuming, manual processes amongst prescribers, health plans ...
(Date:3/31/2015)... Mar. 27, 2015 Research and Markets ... "Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative ... report to their offering. The global intraoperative ... of 3.5% from 2014 to 2019 It ... a number of forces that favor this market. The ...
Breaking Medicine Technology:Government of Canada hosts roundtable discussion to advance Canada's work on antimicrobial resistance 2Government of Canada hosts roundtable discussion to advance Canada's work on antimicrobial resistance 3Government of Canada hosts roundtable discussion to advance Canada's work on antimicrobial resistance 4Point-of-Care Partners Launches the ePA State Navigator 2Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market 2015-2019 2
...  Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today ... by prescription nationwide. This is the only fluoxetine ... The U.S. Food and Drug Administration (FDA) approved ... tablets in October 2011. (Photo: ...
... Brand™ announces the release of VB ... for expanding serialization and traceability regulations for pharmaceutical, biologics, medical ... E nterprise 4.0 for Life Sciences adds support for ... interface standard. Verify Brand™ has also gone beyond ...
Cached Medicine Technology:Edgemont - New Fluoxetine Tablets, 60 mg Now Available 2Edgemont - New Fluoxetine Tablets, 60 mg Now Available 3Edgemont - New Fluoxetine Tablets, 60 mg Now Available 4Edgemont - New Fluoxetine Tablets, 60 mg Now Available 5Edgemont - New Fluoxetine Tablets, 60 mg Now Available 6Verify Brand™ Announces the Release of VB Enterprise 4.0 for Life Sciences 2Verify Brand™ Announces the Release of VB Enterprise 4.0 for Life Sciences 3
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 San ... and the international children’s medical charity, Operation Smile, ... new global partnership. , Campaign Details: RxOrganics is ... Rxmedical line to Operation Smile throughout 2015. RxOrganics ... on such sales so that every order placed online ...
(Date:4/1/2015)... TCS Healthcare Technologies (TCS), a leading ... management and population health arenas, is pleased to announce ... which is fully integrated with the ACUITY platform. , ... p.m. ET, will be led by Jeff Frater, RN, ... explore the feature-rich portal as well as the importance ...
(Date:4/1/2015)... 2015 Nike Golf Camps has expanded ... Arizona and Florida. These programs are specifically designed for ... in a golf-intensive environment and to learn about the ... of Arizona coaching legend, Rick LaRose, spends significant time ... gaps as it pertains to the recruiting and college ...
(Date:4/1/2015)... Oak Brook, IL (PRWEB) April 01, 2015 ... unfortunately benefited greatly from climate change in recent years, ... will develop an allergic reaction if exposed to poison ... as outdoor enthusiasts and families prepare for summer adventures ... of an uncomfortable poison plant reaction is greater than ...
(Date:3/31/2015)... 31, 2015 Due to its ... hire more caregivers, staffing personnel, and marketing managers, ... managers within the Greater Los Angeles area. In ... 1Heart Caregiver University has firmed up its training ... to provide quality in-home care through a client-centered ...
Breaking Medicine News(10 mins):Health News:RxOrganics Forges Unique Partnership to Bring More Smiles to Underserved Global Heath Communities 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:1Heart Ends 1st Quarter of the Year With 1Heart Caregiver University Training of New Staff and Commits To Provide More Jobs For Year 2015 2Health News:1Heart Ends 1st Quarter of the Year With 1Heart Caregiver University Training of New Staff and Commits To Provide More Jobs For Year 2015 3
... veterans face some unique health issuesMINNEAPOLIS/ST. PAUL, Minn., May ... to school this fall as a result of the ... ensure student veterans, unique needs are met, according to ... the University of Minnesota and Minnesota State ...
... Angeles, London, New Delhi, Singapore and Washington DC (May 29, 2009) ... an over-the-counter, rapid HIV test for home use, according to a ... MDM ) which is published by SAGE. , As ... are at greater risk for HIV infection will not be able ...
... DALLAS, May 29 BeaconEquity.com announces availability of alerts on ... trading. The alerts include recent news, trading activity and technical ... stock alerts for free by visiting ... Angiotech Pharmaceuticals Inc. (Nasdaq: ANPI ), Peregrine Pharmaceuticals ...
... disease, risks may outweigh benefits, research suggests , , ... attack risk in people with no previous history of ... say British researchers who analyzed the results of 22 ... this group of patients is uncertain because the benefits ...
... & Lomb,s Expanding Ocular Pharmaceuticals Portfolio and Offers New ... Pathogens(1) - , MADISON, N.J., May 29 Bausch ... announced that the U.S. Food and Drug Administration (FDA) ... the treatment of bacterial conjunctivitis, commonly referred to as ...
... at Digestive Disease Week, addressing the topic of invention of new ... ... May 29, 2009 -- Zeus, Inc., a leader in polymer extrusions ... Digestive Disease Week in Chicago on June 1, 2009. Zeus ...
Cached Medicine News:Health News:Student Veteran Health Examined in First-of-Its-Kind Study by University of Minnesota/Minnesota State Colleges and Universities 2Health News:Student Veteran Health Examined in First-of-Its-Kind Study by University of Minnesota/Minnesota State Colleges and Universities 3Health News:FDA ignores critical information on home HIV tests 2Health News:Beacon Equity Issues Stock Alerts on Leading Pharmaceutical Giants 2Health News:Beacon Equity Issues Stock Alerts on Leading Pharmaceutical Giants 3Health News:Value of Taking Aspirin to Cut Heart Risk Varies 2Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 2Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 3Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 4Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 5Health News:Zeus to Present at Digestive Disease Week in Chicago 2
Thermal Seal, Clear, Bulk...
Acetate Plate Sealers 100/Box...
... seals provide an adhesive-based sealing option for ... adhesive layer ensures secure sample storage or ... sealing during thermal cycling when supplemental pressure ... perforated end-tabs can be removed when using ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Medicine Products: